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ABSTRACT 
 
Multiple Sclerosis (MS) is characterized by multiple areas of inflammation, demyelination 
and neurodegeneration. Infiltrating Th1 CD4+ T cells secrete proinflammatory cytokines. 
They stimulate the release of some cytokines, expression of adhesion molecules and these 
cytokines may cause damage to the myelin sheath and axons.  
In this study, we analyzed plasma levels and gene expressions of five important cytokines 
in the new diagnosed MS Patients by ELISA and Real time PCR. PCR amplifications were 
performed to determine the IL-17, IL-23, IL-10, IL-27 and TGF-β mRNA expression levels using 
the SYBR Green PCR Kit. 
Our results showed significant decrease in IL-10, IL-27 and TGF-β but there was no 
significant difference in the IL-17 and IL-23 between patients and healthy controls. 
Altogether, our results indicated that dysregulation of cytokines, mainly increased expression 
of pro-inflammatory cytokines and decreased expression of inhibitory cytokines occurred in 
MS patients.  
This study may shed light to the probable role of these cytokines in neurodegeneration 
mechanism and current or future use of cytokines in managing and treatment of multiple 
sclerosis.   
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INTRODUCTION 
 
Multiple Sclerosis (MS), a chronic inflammatory  
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(CNS), is the most common cause of neurological 
disability mainly affecting young adults.
1
 The 
incidence and prevalence of MS in Iran has been 
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growing without explanation, especially in females.
2
 It 
is generally believed that MS is an autoimmune 
disorder.
3-5
 
In addition to T helper-1 (Th1)-lymphocytes, Th17-
cells that secrete interleukin (IL)-17 are believed to be 
important in the pathogenesis of MS.
6
 A study has 
demonstrated that the IL-23/Th17 pathway plays a role 
in EAE.
7
 The important role of IL-23 in the expansion 
of CNS inflammation was a reflection to be due to its 
role in promoting IL-17 production, but recently it has 
been found that IL-23 has an important role in homing 
to the CNS and survival of myelin-specific T 
lymphocytes in the CNS microenvironment.
8
 IL-23 
may affect T cell trafficking by making changes in 
chemokine receptors, such as chemokine receptor 6 
(CCR6) that are highly expressed on human Th17 
lymphocytes.
9,10
 IL-23 driven Th17 lymphocytes also 
cause inflammation of the optic nerve and create 
lesions similar to Neuromyelitis Optica.
11
 These data 
suggest that the effector T lymphocyte cytokines can 
play important role in the migration of the T cells to 
specific regions within the CNS. Unusual recruitment 
of these immune cells cause functional losses.
12
 
The essential phase of inflammation in the 
autoimmune disorders is altered balances between pro-
inflammatory versus anti-inflammatory cytokines in the 
disease process. MBP-specific T lymphocytes isolated 
from MS patients have shown that T lymphocytes have 
an essential role in the MS pathology.
13,14
 High levels 
of Th1 cytokines are mostly obvious during EAE/MS 
relapse, but there are high levels of Th2 cytokines 
during remission in MS patients.
15
 Altered reactivity of 
PBMC and their cytokines may influence the clinical 
course of MS and also altered reactivity of immune 
system cells modulate this disease.
16
 
Symptoms worsen in relapsing/remitting MS 
patients after IFN-γ administration. This is also shown 
in other Th1-related disorders, whereas it is not shown 
in Th2 type disorders.
17,18
 
Mice with deficiency in IL-12α (IL-12p35, part of 
the Th1 prototype), are susceptible to EAE. In the same 
way, IL-12R β2-deficient mice expand severe clinical 
manifestations of EAE, whereas mice with deficiency 
in IL-12p40 are resistant to EAE.
19-21
 These 
paradoxical data show that an imbalance in the 
Th1/Th2 cells cannot elucidate the overall 
immunopathogenic mechanisms of MS. IL-23, not IL-
12, is crucial for induction of EAE.
22
 Moreover, Th17 
cells are expanded by IL-23, and can induce EAE when 
transferred into naive mice adoptively.
23,24
 These Th17 
lymphocytes were significantly reduced in the CNS of 
mice with IL-23p19-deficiency. These results 
suggested that Th17 lymphocytes exacerbate 
autoimmunity.
25,26
  
The MS cytokine profile was more clarified after 
Th17 discovery
10
 and one study showed that the levels 
of IL-17 produced by MBP-stimulated peripheral blood 
cells was associated with the lesions activity in MS 
patients.
27
  
TGF-β is a major cytokine in the production of 
regulatory T lymphocytes (Tregs). These cells inhibit 
the autoimmune responses and protect CNS against 
inflammatory damages. Tregs play important role in the 
regulation of Th1/Th2 and Th17 lymphocytes. As a 
result, the production of pathogenic Th17 cells 
provokes autoimmunity, but the generation of Tregs 
inhibits autoimmune tissue damage.
28
 On the other 
hand, IL-27 is an inhibitor of Th17 lymphocyte 
differentiation and prevent inflammatory demyelination 
of EAE in animal models.
29
 Some studies showed that 
IL-12, IL-23 and IL-27 are associated to the group 
which stimulates Th1 type of immune response.
30
 
Jager et al. studies have shown that Th1, Th17, and 
Th9 lymphocyte, but not Th2 cells, induce EAE. In 
addition, each T-cell subset induces disease in an 
individual pathological approach. The pathological 
variation in MS lesions may result in different effects 
of reactive T lymphocytes against myelin.
31,32
 
Treatment with IFN-β can decrease IL-23 mRNA 
levels
33
 and suppress human Th17 lymphocyte subset 
differentiation, hence the Th17 may be an additional 
target of IFN-β therapy.34 IFN-β plays an important 
role in inhibiting Th17 cells by its effect on innate 
immune system cells and stimulates IL-27 synthesis
35
 
and it may also induces IL-10 production which act as a 
negative regulatory cytokine.
33
 
The failure of IFN-β therapy in some 
relapsing/remitting MS patients can be related to high 
levels of IL-17F cytokine in these patients.
36
 This 
cytokine suppresses Th17 expansion in MS, and may 
have an effect on the clinical symptoms in patients.
37
 
Consequently, the result of most related studies 
endorsed very important role of cytokine profile in 
disease onset and its clinical progress.  
The aim of the present study was to evaluate plasma 
levels of these cytokines in MS patients in comparison 
with healthy controls to find probable association 
between cytokine profile and MS disease.  
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MATERIALS AND METHODS 
 
This study was approved by the Ethical Committee 
on Human Research, Shahre Kord University of 
Medical Sciences. The volunteers were referring to MS 
Clinic of Isfahan Kashani Hospital. They were 
informed about the procedure of the study and those 
who were willing to participate, donated blood sample 
and signed an informed consent. 
  
Study Groups 
45 newly-diagnosed MS patients [33 females and 
12 males, (39 RRMS, 1 PPMS and 5 SPMS)] and 45 
age- and gender-matched healthy control (HC) 
individuals were recruited in the study. New cases were 
those who had at least one episode of focal 
neurological signs, symptoms such as Fatigue and 
numbness, weakness in a leg or legs, visual problems 
and positive Magnetic resonance imaging MRI findings 
(according to "Revised Mc Donald criteria" and 
exclusion of other possible differential diagnosis 
(clinically and para clinically). All samples were taken 
during relapse but before taking any drugs including 
"Methyl prednisolone, Beta-interferone,) or immuno 
suppressives and immuno modulators. The members of 
healthy control group were selected from Blood Bank 
organization donors. The donors' health was confirmed 
by Physician of this Organization. Control group 
members did not have any drug administration. All 
blood samples were collected during relapse phase 
before any drug administration. Patients were clinically 
diagnosed with MS according to the McDonald criteria 
with EDSS between 0-3.
38
 
 
Isolation of Plasma and PBMC from Whole Blood 
Blood samples were obtained from patients and 
healthy volunteers and transported on ice to the 
laboratory. Plasma were removed and kept frozen at 
−80°C until cytokine determination. Peripheral blood 
mononuclear cells (PBMCs) were isolated using Ficoll-
Hypaque density gradient (Lymphodex, Germany). 
PBMCs were washed three times with Phosphate 
buffered saline (PBS) and the pellet was resuspended in 
a RNA protect cell solution (Qiagen, Germany) and 
stored at -80°C until use for RNA extractions.  
 
RNA Extraction and cDNA Synthesis  
Total RNA was isolated from cell lysate of 10
6 
PBMC using miRCURY RNA Isolation Kit (Exiqon 
Denmark) under RNase-free condition according to the 
manufacturer’s protocol. The quality and quantity of 
RNAs were checked using agarose gel electrophoresis 
and spectrophotometric analysis. DNase treated RNA 
was reverse transcribed using RevertAid First Standard 
synthesis kit (Fermentas, Lithuania) according to the 
manufacturer’s instruction. The samples were then 
reverse transcribed using 0.5 µg of RNA under 
conditions of 65 °C for 5 min, 25 °C for 5 min, 42 °C 
for 60 min and 70 °C for 5 min. 
 
Real-Time PCR  
PCR amplifications were performed to determine 
the IL-17, IL-23, IL-10, IL-27 and TGF-β mRNA 
expression levels using the SYBR Green PCR Kit 
(Fermentas, Lithuania) in a total volume of 25 µl, 
containing 1.5 µl cDNA samples, 5 picomoles of each 
primer and 12.5 µl of SYBR Green PCR Master Mix. 
The PCR primers that were used for real-time PCR are 
shown in Table1. Real-time reverse transcription PCR 
(RT-PCR) was run on the ABI Step one Plus (Applied 
Biosystems USA). The PCR conditions were as 
follows: initial denaturation at 95 °C for 10 min, 
followed by 40 cycles of 95 °C for 15 seconds and 
60°C for 60 seconds. Melting curve analysis of the 
PCR product was performed after amplification  
to identify all PCR products. Real time PCR reactions 
were performed in triplicate. The Ct values for  
each gene were normalized to endogenous control 
gene, Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), and calculation was performed using 2
-Δct
 
method. 
 
Cytokine Analysis 
Plasma levels of MS-relevant cytokines (IL-10, IL-
17, IL-23, IL-27, and TGF-β) were determined by 
ELISA system using ELISA Reader (Hyperion, USA) 
IL-17A, IL-10 and TGF-β were assessed using 
commercial ELISA kits from Bender Med Systems 
(Vienna, Austria), and IL-23 and IL-27 cytokines were 
assessed using Abcam company kits (Abcam, UK) 
according to the manufacturer’s instructions. 
The absorbance of each well was read at 450nm and 
the concentrations were determined using standard 
curves. Cytokine levels were expressed as picogram/ml 
(pg/ml). 
 
Statistical Analysis 
Statistical analysis was performed using SPSS 
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version 16. Student's independent t-test was used to 
determine the significant difference; P<0.05 was 
considered as significant. 
 
RESULTS 
 
The basic information of the 45 recruited patients 
(M=12, F=33) and controls (M=12, F= 33) is 
summarized in Table2. There was no significant 
difference in the mean age of case and control groups. 
 
Real Time PCR IL-17, IL-10, IL-23, IL-27 and 
TGF-β Gene Expression 
The mRNA levels of IL-17, IL-10, IL-23, IL-27, 
TGF-β and GAPDH as a housekeeping gene were 
quantified by quantitative Real-time PCR. The mRNA 
mean expressions of IL-17, IL-10, IL-27, TGF-β  
were different in patient and control groups, which 
displayed a significant increase in IL-17 and decrease 
in IL-10, IL-27 and TGF-β in patients group (p=0.015, 
p=0.005, p=0.027, p<0.001). The mRNA mean 
expressions in IL-23 was not significantly different in 
the two groups, however, it was higher in patients 
group (p=0.079) (Table 3 and Figure1). 
 
ELISA Evaluation Result 
In the present study plasma levels of IL-17, IL-10, 
IL-23, IL-27, and TGF-β were evaluated in patients  
and controls. The results showed a considerable 
increase in the plasma levels of IL-17A in MS patients 
compared with healthy controls, however, this 
difference was not significant (p=0.065).The plasma 
levels of IL-23 was higher in patients group, however, 
it was not significant (p=0.078).The plasma levels of 
IL-10, IL-27 and TGF-β in MS patients were 
significantly lower than healthy controls (p<0.001, 
p<0.001, and p=0.013) (Table 3 and Figure 2). 
 
 
Table1. Primers used in real-time polymerase chain reaction. 
Target gene Primers Product size 
Human IL-17 A              Forward: 
                                       Reverse: 
5'- CTGTCCCCATCCAGCAAGAG -3' 
5′- AGGCCACATGGTGGACAATC -3' 
132 
 
Human IL-10                  Forward: 
                                        Reverse: 
5'-   GCCGTGGAGCAGGTGAAG-3' 
5′- AGTCGCCACCCTGATGTCT-3' 
144 
 
Human IL-23p19            Forward: 
                                        Reverse: 
5'-GTGGGACACATGGATCTAAGAGAAG-3' 
5′- TTTGCAAGCAGAACTGACTGTTG-3' 
124 
 
Human IL-27                  Forward: 
                                        Reverse: 
5'- CCTGGTTCAAGCTGGTGTCT -3' 
5'- CTCCTGGCAGGTGAGATTCC -3' 
167 
 
Human TGF-β                Forward: 
                                        Reverse: 
5'-  CAGCAACAATTCCTGGCGATA-3' 
5′- AAGGCGAAAGCCCTCAATTT-3' 
136 
 
Human GAPDH             Forward: 
                                       Reverse: 
5'-CCACTCCTCCACCTTTGACG -3' 
5′- CCACCACCCTGTTGCTGTAG-3' 
107 
 
 
 
 
Table2. Demographic characteristics of MS patients and healthy Controls studied. 
Variables 
Groups 
P value MS 
(n=45) 
Control 
(n=45) 
Age (year) 32.15±10.69 33.28±9.92 0.60 
Gender (Female/male) 33/12 33/12 1 
Age range 17-58 17-58 1 
Data are Mean ± SD   P values derived from T-test 
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Figure 1. mRNA expression of TGF-β, IL-10, IL-27, IL-23, and IL-17 from PBMC in MS patients and healthy controls. Data 
are expressed as the mean ± standard deviation of the mean.  
 
 
Figure 2. Plasma cytokine levels in MS patients and healthy controls. Data are expressed as the mean ± standard deviation of 
the mean.  
 
Table 3. Comparison of cytokine levels and relative mRNA expression in MS patients and healthy controls 
Variables 
MS 
(n=45) 
Control 
(n=45) 
P Value 
IL-17A Cytokine Level 
Il-17 Relative mRNA Expression   
81.91±15 
0.071354±0.0200 
35.24±10 
0.044097±0.0250 
0.065 
0.015 
IL-10 Cytokine Level 
Il-10 Relative mRNA Expression   
56.13±23 
0.0329±0.0100 
519.66±65 
0.0759±0.0267 
<0.001 
0.005 
IL-23 Cytokine Level 
Il-23 Relative mRNA Expression   
194.089±26 
0.0729±0.0100 
158.51±17 
0.0533±0.0200 
0.078 
0.079 
IL-27 Cytokine Level 
Il-27 Relative mRNA Expression   
144.86±27 
0.0531±0.0287 
266.48±45 
0.0800±0.0254 
<0.001 
0.027 
TGF-β Cytokine Level 
TGF-β Relative mRNA Expression   
989.68±155 
0.0278±0.0150 
1992.4±220 
0.0618±0.0146 
0.013 
<0.001 
Data are Mean ± SD   P values derived from T-test 
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DISCUSSION 
 
In the present study, we found an alteration in 
plasma levels of Pro-inflammatory (IL-17, IL-23) and 
immunoregulatory cytokines (IL-10, IL-27 and TGF-β) 
in newly-diagnosed patients with MS. 
Our study has also shown that the gene expression 
of these cytokines was changed in PBMC of these 
cases in comparison with healthy controls. Our data 
demonstrated gene expression of IL-17 in the patients 
group was significantly higher than control group and 
plasma level of this cytokine in the patients group was 
increased, however, it was not significant. This can be 
explained by the fact that gene expression does not 
necessarily result in translation into complete and 
functional protein, and post-translational modifications 
or regulatory systems can suppress or limit protein 
secretion. However, some studies have shown that IL-
17 level of MS patients are significantly higher than 
controls. Matusevicius et al. also have shown that in 
patients with MS, a high copy number of IL-17-mRNA 
in mononuclear lymphocytes in the cerebrospinal fluid 
(CSF) was present in comparison with the peripheral 
blood.
39
 A study in Iran demonstrated significant 
difference in IL-17 between patients and control 
groups.
40
 However, Kallaur et al findings did not show 
significant differences in IL-17 between case and 
control groups.
41
 This discrepancy may be a result ofthe 
diversity in patients. In our study, we used newly-
diagnosed cases of MS before any treatment. On the 
other hand, negative feedback regulatory mechanisms 
may affect IL-17 protein expression and decreased IL-
17 production. In addition, this alteration may result in 
a difference in regulatory factors, enhancers and 
inhibitor molecules due to primary expression of 
cytokines.
42
 
The present study indicated that although gene 
expression and plasma level of IL-23 was not 
significantly different between the two groups, 
expressions were higher in patients group. High levels 
of IL-23 are associated with increasing IL-17 secretion 
from T cells. Similar to our result, a study by Vaknin-
Dembinsky et al. showed that monocyte-derived 
dendritic cells in MS patients produce greater amounts 
of IL-23 compared with healthy controls.
43
 
Another study has reported that decrease of IL-17 
inhibits neutrophil recruitment and a secondary damage 
in CNS by matrix metalloproteases release. On the 
other hand, the reduction of IL-23 prevents CNS 
inflammation. These data also demonstrated that 
deficiency of IL-17 is the cause of less severe EAE but 
deficiency of IL-23 causes no disease.
12
 
On the other hand, our result demonstrated that IL-
10, IL-27 and TGF-β levels in the patients group were 
significantly lower than the control group. These 
findings demonstrate inhibitory role of these cytokines 
on the immune system cells. These results agree with 
the findings of other studies which indicated that IL-10 
cytokine is decreased during relapses
44
 and a number of 
studies make clear inhibitory effects of IL-10 in 
MS.
45,46
 
Mayer et al. reported that TGF-β1 secretion by 
regulatory T lymphocytes inhibit the development of 
EAE.
47
 In addition, exogenous TGF-β1 can prevent the 
development of EAE and the severity of the disease 
was increased by TGF-β1 neutralization. Also 
appearance of symptoms in MS patients has been 
associated with TGF-β1 levels.48 Differentiation of 
Th17 lymphocytes is mediated by IL-6 and TGF-β. 
Our results showed that gene expressions and 
plasma level of IL-27 were significantly lower in 
patients group compared to healthy controls. IL-27 has 
inhibitory role on production of IL-6 and TGF-β and 
suppresses Th17 cell production indirectly. On the 
other hand, IL-27 generally has anti-inflammatory 
function and may be regarded as a suppressor of 
autoimmunity.
49
 Furthermore, in the EAE model, IL-27 
is a negative regulator of Th17 lymphocyte 
differentiation and can inhibit inflammatory 
demyelization.
29
 
IL-27 plays a role in expansion and differentiation 
of IL-10-producing regulatory T cells through 
promoting the expression of three important molecules: 
ICOS (an inducible T-cell costimulator), c-Maf (the 
basic leucine-zipper transcription factor Maf) and IL-
21.
50
 
Fitzgerald DC et al. have shown that in IL-27-
deficient mice, EAE was more severe but CNS 
inflammatory infiltration was noticeably reduced in the 
IL-27 treated mice.
51
 Latest studies have confirmed a 
pro-inflammatory role of IL-27 in both innate and 
adaptive immune responses in chronic diseases.
52
 
 Some drugs in MS patients act through cytokine 
alterations. It was reported that mitoxantrone treatment 
acts in MS patients through the development of Th2 
cytokines
53
 and Glatiramer acetate (GA) boosts the 
suppressive effects of Tregs in MS.
54
 
In conclusion, our results showed that a 
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dysregulation of cytokines, mainly decreased 
expression of inhibitory cytokines and increased 
expression of pro-inflammatory cytokines, occurred in 
MS patients. Further studies with more samples should 
be done to explore the role of cytokines in MS patients. 
This information is helpful for suggesting cytokines as 
new candidates in diagnostic and therapeutic 
approaches. 
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